Dechra reports rise in revenue and profits

In the year ended June 30, group revenue increased by 5.5 per cent from 350m to 369.4m. Adjusted profit before taxation rose 11.3 per cent to 26.1m.

Dechra employs more than 200 people at its Dales Pharmaceuticals manufacturing plant in Skipton, North Yorkshire.

Michael Redmond, the company's chairman, said: "Although continuing to show growth, most of the markets in which we trade remain competitive with the impact of any future general economic weakness being uncertain.

"Despite this, our product development pipeline delivers new products year on year, our international pharmaceutical and diets businesses are delivering good growth and our established UK service business continues to increase its profitability.

"We anticipate that, in the long-term, market growth will return to historic levels. We therefore remain confident about our future growth prospects."